AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 280: E443-E449, 2001;
0193-1849/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silvestre, R. A.
Right arrow Articles by Marco, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silvestre, R. A.
Right arrow Articles by Marco, J.
Vol. 280, Issue 3, E443-E449, March 2001

Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas

R. A. Silvestre1, J. Rodríguez-Gallardo1, C. Jodka2, D. G. Parkes2, R. A. Pittner2, A. A. Young2, and J. Marco1

1 Clínica Puerta de Hierro and Department of Physiology, Universidad Autónoma de Madrid, 28035 Madrid, Spain; and 2 Amylin Pharmaceuticals Inc., San Diego, California 92121

Amylin, a peptide hormone from pancreatic beta -cells, is reported to inhibit insulin secretion in vitro and in vivo and to inhibit nutrient-stimulated glucagon secretion in vivo. However, it has been reported not to affect arginine-stimulated glucagon secretion in vitro. To resolve if the latter resulted from inactive peptide (a problem in the early literature), those experiments were repeated here with well-characterized peptide and found to be valid. In isolated perfused rat pancreas preparations, coperfusion with 1 nM amylin had no effect on arginine-, carbachol-, or vasoactive intestinal peptide-stimulated glucagon secretion. Amylin also had no effect on glucagon output stimulated by decreasing glucose concentration from 11 to 3.2 mM or on glucagon suppression caused by increasing glucose from 3.2 to 7 mM. Amylin at 100 nM had no effect in isolated islets in which glucagon secretion was stimulated by exposure to 10 mM arginine, even though glucagon secretion in the same preparation was inhibited by somatostatin. In anesthetized rats, amylin coinfusion had no effect on glucagon secretion stimulated by insulin-induced hypoglycemia. To reconcile reports of glucagon inhibition with the absence of effect in the experiments just described, anesthetized rats coinfused with rat amylin or with saline were exposed sequentially to intravenous L-arginine (during a euglycemic clamp) and then to hypoglycemia. Amylin inhibited arginine-induced, but not hypoglycemia-induced, glucagon secretion in the same animal. In conclusion, we newly identify a selective glucagonostatic effect of amylin that appears to be extrinsic to the isolated pancreas and may be centrally mediated.

rat pancreas; isolated islets; in vivo; amylin; glucagon


This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. D. Roth, H. Maier, S. Chen, and B. L. Roland
Implications of Amylin Receptor Agonism: Integrated Neurohormonal Mechanisms and Therapeutic Applications
Arch Neurol, March 1, 2009; 66(3): 306 - 310.
[Full Text] [PDF]

Home page
 DiabetesHome page
O. Schmitz, B. Brock, and J. Rungby
Amylin Agonists: A Novel Approach in the Treatment of Diabetes
Diabetes, December 1, 2004; 53(suppl_3): S233 - S238.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. B. Buse, C. Weyer, and D. G. Maggs
Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy
Clin. Diabetes, July 1, 2002; 20(3): 137 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
Diabetes Care, April 1, 2002; 25(4): 724 - 730.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online